RECURRENT GRADE 1 FOLLICULAR LYMPHOMA

This study is testing the safety and effectiveness of combining two drugs, nivolumab and lenalidomide, for patients with non-Hodgkin or Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal is to see if using these drugs together can better contr…

This early-stage trial is testing a new combination of three drugs for people whose non-Hodgkin lymphoma has come back after previous treatment. The main goal is to find the safest and most effective dose of a new pill (PCI-32765) when given with two existing drugs (rituximab and…

This early-stage study is testing a combination of two drugs, pembrolizumab and vorinostat, for people with certain types of lymphoma that have come back or not responded to prior treatments. The main goals are to check the safety of the combination and find the best dose of vori…

This early-phase study is testing the safety and best dose of a personalized cell therapy for patients with aggressive B-cell lymphomas that have returned or are high-risk. The treatment involves collecting a patient's own immune cells (T cells), genetically modifying them in a l…

This is an early-stage study to find the safest dose of an experimental immunotherapy drug called MEDI-570. It is for adults with specific types of advanced T-cell lymphoma that have come back or stopped responding to previous treatments. The main goals are to check for side effe…

This study is testing whether the immunotherapy drug nivolumab can help control blood cancers that have returned, stopped responding, or are still detectable after a patient has already received CAR-T cell therapy. It is for adults with specific types of lymphoma, leukemia, or mu…

This study tested a daily pill called ibrutinib in 41 patients with follicular lymphoma, a type of blood cancer, that had returned or stopped responding to previous treatments. The main goal was to see how well the drug could shrink the cancer and control the disease. Researchers…

This study is testing whether a combination of two drugs, epcoritamab and tazemetostat, is safe and effective for adults with follicular lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if this two-drug approach can help control the cance…

This study is testing whether combining the immunotherapy drug pembrolizumab with the standard antibody rituximab (with or without the drug lenalidomide) can help control lymphoma that has come back after previous treatment. It is for adults with specific types of B-cell lymphoma…

This study is testing a personalized plan to manage cytomegalovirus (CMV), a common and potentially serious infection, in patients who have received a donor stem cell transplant for blood cancers or disorders. The plan involves closely monitoring the virus level and the patient's…